NCT02470767View on ClinicalTrials.gov

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

CompletedOBSERVATIONAL
Enrollment

792

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
StrokePrevention and ControlAtrial Fibrillation
Interventions
DRUG

Direct Oral Anticoagulant (DOAC)

Treatment pattern following the summary of product characteristics

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02470767 - An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres | Biotech Hunter | Biotech Hunter